Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.
Tobias Huber, MD
Advertisement
Tobias Huber, MD, is President of the International Society of Glomerular Disease, Chair of the Center of Internal Medicine; Director of the III. Department of Medicine (Nephrology, Rheumatology, Endocrinology and Transplantation); and Director of the Hamburg Center for Kidney Health at the University Medical Center Hamburg-Eppendorf.
Articles by Tobias Huber, MD
Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.
The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.
PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.
Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.
APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.
Rapid advances in glomerular disease, from single-cell tech to biomarkers and phase 3 trials, are reshaping diagnosis and treatment.
Advertisement
Latest Updated Articles
ISGD and the Fastest 5 Years in Glomerular DiseaseMarch 6th 2026
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5